Assessment of PET Tracers to Evaluate T Cell Change and Activation in Relation to Immunotherapy Treatment Response in Non-Small Cell Lung Cancer

The iRelate is a PET imaging trial to compare two upcoming and promising T cell PET tracers. Following chemo-immuno therapy, as part of standard care, NSCLC patients will be recruited to receive two PET scans, shortly before their surgery. Both PET scans will be compared to each other, as well as compared to the pathological analysis of the resected tumor. This study will provide detailed information on the unique as well as additive capacities of imaging biomarkers derived from the immune cell targeting PET tracers.

Trial Details

NCT ID
NCT06457789
Phase
NA
Sponsor
Amsterdam UMC, location VUmc
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • [18F]F-AraG PET imaging
  • [89Zr]Zr-Df-Crefmirlimab PET imaging
Locations (sample)
  • Amsterdam, North Holland, Netherlands|52.37403,4.88969

Key Eligibility Criteria

  • Histologically confirmed NSCLC
  • T1-4N0-2, lesion size of ≥2cm, at time of the restaging FDG PET/CT
  • Planned to undergo resection after chemo-IO according to routine treatment guidelines
  • Willing and able to provide written informed consent for the trial

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →